Product Description
TPX-100 is a candidate first-in-class disease modifying osteoarthritis drug(DMOAD).
Mechanisms of Action: ITG Binder
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: OrthoTrophix
Company Location: Western America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Osteoarthritis, Knee
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06865079 |
TPX-100-6 | P2 |
Recruiting |
Osteoarthritis, Knee |
2027-05-25 |
50% |
2025-05-07 |
Primary Endpoints|Start Date|Treatments|Trial Status |